UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases

Cancer, 2018-02, Vol.124 (4), p.807-815

2018

Volltextzugriff (PDF)

PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant Cancers

Clinical cancer research, 2019-07, Vol.25 (13), p.3759-3771

2019

Volltextzugriff (PDF)

Smoking, p53 mutation, and lung cancer

Molecular cancer research, 2014-01, Vol.12 (1), p.3-13

2014

Volltextzugriff (PDF)

Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8 + T cell exhaustion

Nature communications, 2020-09, Vol.11 (1), p.4520-4520, Article 4520

2020

Volltextzugriff (PDF)

The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response

British journal of cancer, 2021-03, Vol.124 (5), p.857-859

2021

Volltextzugriff (PDF)

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

Clinical cancer research, 2013-11, Vol.19 (22), p.6322-6328

2013

Volltextzugriff (PDF)

Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells

Molecular cell, 2019-12, Vol.76 (5), p.838-851.e5

2019

Volltextzugriff (PDF)

Comparative genomics of high grade neuroendocrine carcinoma of the cervix

PloS one, 2020-06, Vol.15 (6), p.e0234505-e0234505

2020

Volltextzugriff (PDF)

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells

Nature (London), 2017-06, Vol.546 (7656), p.168-172

2017

Volltextzugriff (PDF)

A pan-cancer proteomic perspective on The Cancer Genome Atlas

Nature communications, 2014-05, Vol.5 (1), p.3887-3887, Article 3887

2014

Volltextzugriff (PDF)

Assessing the clinical utility of cancer genomic and proteomic data across tumor types

Nature biotechnology, 2014-07, Vol.32 (7), p.644-652

2014

Volltextzugriff (PDF)

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

Nature communications, 2021-05, Vol.12 (1), p.2606-2606, Article 2606

2021

Volltextzugriff (PDF)

Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer

Radiotherapy and oncology, 2018-03, Vol.126 (3), p.499-505

2018

Volltextzugriff (PDF)

Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus

PloS one, 2012-06, Vol.7 (6), p.e36116

2012

Volltextzugriff (PDF)

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

JNCI : Journal of the National Cancer Institute, 2012-02, Vol.104 (3), p.228-239

2012

Volltextzugriff (PDF)

Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer

PloS one, 2016-04, Vol.11 (4), p.e0152584-e0152584

2016

Volltextzugriff (PDF)

Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer

Gynecologic oncology, 2016-06, Vol.141 (3), p.588-591

2016

Volltextzugriff (PDF)

Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC

Cancer research (Chicago, Ill.), 2021-03, Vol.81 (5), p.1398-1412

2021

Volltextzugriff (PDF)

Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer

Seminars in oncology, 2016-08, Vol.43 (4), p.476-483

2016

Volltextzugriff (PDF)

NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma

Cells (Basel, Switzerland), 2020-12, Vol.9 (12), p.2677

2020

Volltextzugriff (PDF)

Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers

Frontiers in oncology, 2021-10, Vol.11, p.757323-757323

2021

Volltextzugriff (PDF)

The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA

Cancer research (Chicago, Ill.), 2012-05, Vol.72 (9), p.2275-2284

2012

Volltextzugriff (PDF)

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

Molecular cancer, 2024-05, Vol.23 (1), p.115-17, Article 115

2024

Volltextzugriff (PDF)

1 – 25 von 368

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(338)
Mit Volltextzugriff
(339)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(185)
Life Sciences & Biomedicine
(165)
Humans
(136)
Oncology
(128)
Lung Neoplasms - Drug Therapy
(57)
Lung Neoplasms - Genetics
(54)
Female
(51)
Lung Cancer
(47)
Lung Neoplasms - Pathology
(45)
Male
(44)
Tumors
(43)
Animals
(41)
Cell Line, Tumor
(41)
Middle Aged
(31)
Aged
(30)
Small Cell Lung Carcinoma - Drug Therapy
(30)
Mutation
(29)
Adult
(26)
Mice
(26)
Carcinoma, Non-Small-Cell Lung - Genetics
(25)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases

PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant Cancers

Smoking, p53 mutation, and lung cancer

Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8 + T cell exhaustion

The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells

Comparative genomics of high grade neuroendocrine carcinoma of the cervix

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells

A pan-cancer proteomic perspective on The Cancer Genome Atlas

Assessing the clinical utility of cancer genomic and proteomic data across tumor types

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer

Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer

Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer

Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC

Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer

NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma

Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers

The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

Aktive Filter

Suchergebnisse filtern